source
- AstraZeneca halts phase 3 lung cancer trial of bispecific antibody volrustomig after it falls short of KeytrudaAstraZeneca stopped its phase 3 trial of the bispecific antibody volrustomig in metastatic non‑small cell lung cancer after interim data suggested the regimen would not meet the study's primary goa…
- Experts say AI could outperform doctors on basic tasks by 2030Most clinical AI tools being built today are intended to work under a doctor's supervision. Healthcare and venture-capital experts predict that by 2030 AI may independently perform better than phy…